• Jinmiao Lu, Yidie Huang, Qiaofeng Ye, Feineng Shang, Mei Ming, Hong Xu, and Zhiping Li.
• Department of Clinical Pharmacy, Children's Hospital of Fudan University, Shanghai.
• Medicine (Baltimore). 2021 Mar 12; 100 (10): e24919e24919.

IntroductionHydroxychloroquine (HCQ) has received much attention in the treatment of coronavirus disease 2019 recently. However, it can cause irreversible vision loss. Few cases have been reported in pediatric patient with HCQ-related adverse reactions. Appropriate administration and early disease recognition are important for reducing the adverse drug reactions of HCQ.Patient ConcernsWe report a case of a 14-year-old Chinese girl who sought treatment for rapidly decreasing vision in the left eye over 3 days. The simulation results of the population pharmacokinetic model of HCQ revealed that the plasma concentration of HCQ abnormally increased before the visual acuity of the eye decreased.DiagnosisShe was diagnosed as HCQ related drug adverse reaction.InterventionsThe daily dose of HCQ for this patient was adjusted from 100 mg/d to 50 mg/d.OutcomesFollow-up for 6 months showed no more vision loss recurrence. However, the existing decreased visual acuity of the eye did not recover either.ConclusionAlthough decreased visual acuity is an infrequent symptom, ophthalmologists should be aware of the possibility of HCQ concentration enrichment and consider minimizing HCQ use when a child with renal hypofunction seeks treatment for shortsightedness.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

30 keywords...

hide…